STAP-2 protein promotes prostate cancer growth by enhancing epidermal growth factor receptor stabilization

Signal-transducing adaptor family member-2 (STAP-2) is an adaptor protein that regulates various intracellular signaling pathways and promotes tumorigenesis in melanoma and breast cancer cells. However, the contribution of STAP-2 to the behavior of other types of cancer cells is unclear. Here, we show that STAP-2 promotes tumorigenesis of prostate cancer cells through up-regulation of EGF receptor (EGFR) signaling. Tumor growth of a prostate cancer cell line, DU145, was strongly decreased by STAP-2 knockdown. EGF-induced gene expression and phosphorylation of AKT, ERK, and STAT3 were significantly decreased in STAP-2–knockdown DU145 cells. Mechanistically, we found that STAP-2 interacted with EGFR and enhanced its stability by inhibiting c-CBL–mediated EGFR ubiquitination. Our results indicate that STAP-2 promotes prostate cancer progression via facilitating EGFR activation.

[1]  A. Sorkin,et al.  Endocytosis and signalling: intertwining molecular networks , 2009, Nature Reviews Molecular Cell Biology.

[2]  A. Yoshimura,et al.  Signal-Transducing Adaptor Protein-2 Regulates Integrin-Mediated T Cell Adhesion through Protein Degradation of Focal Adhesion Kinase1 , 2007, The Journal of Immunology.

[3]  Y. Huang,et al.  Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells , 2010, Oncogene.

[4]  A. Yoshimura,et al.  STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis , 2018 .

[5]  C. Korch,et al.  Molecular characterization of human prostate carcinoma cell lines , 2003, The Prostate.

[6]  S. Akira,et al.  Negative Regulation of Melanoma Differentiation-associated Gene 5 (MDA5)-dependent Antiviral Innate Immune Responses by Arf-like Protein 5B* , 2014, The Journal of Biological Chemistry.

[7]  J. Menéndez,et al.  Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. , 2012, International journal of oncology.

[8]  A. Gemma,et al.  F1000 highlights , 2010 .

[9]  A. Yoshimura,et al.  STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. , 2009, Biochemical and biophysical research communications.

[10]  A. Yoshimura,et al.  Involvement of STAP‐2 in Brk‐mediated phosphorylation and activation of STAT5 in breast cancer cells , 2011, Cancer science.

[11]  Y. Yarden,et al.  Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases , 2004, Oncogene.

[12]  Antony W Burgess,et al.  Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.

[13]  Z. Kam,et al.  c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. , 1998, Genes & development.

[14]  A. Yoshimura,et al.  Physical and Functional Interactions between STAP-2/BKS and STAT5* , 2005, Journal of Biological Chemistry.

[15]  A. Yoshimura,et al.  STAP-2 Protein Expression in B16F10 Melanoma Cells Positively Regulates Protein Levels of Tyrosinase, Which Determines Organs to Infiltrate in the Body* , 2015, The Journal of Biological Chemistry.

[16]  A. Yoshimura,et al.  Signal-Transducing Adaptor Protein-2 Controls the IgE-Mediated, Mast Cell–Mediated Anaphylactic Responses , 2014, The Journal of Immunology.

[17]  I. Mellinghoff,et al.  Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. , 2002, Cancer research.

[18]  M. Rubin,et al.  A phase II trial of gefitinib in patients with non‐metastatic hormone‐refractory prostate cancer , 2007, BJU international.

[19]  I. Madshus,et al.  Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. , 2004, Experimental cell research.

[20]  G. Mills,et al.  Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR , 2011, Oncogene.

[21]  S. Minoguchi,et al.  STAP-2/BKS, an Adaptor/Docking Protein, Modulates STAT3 Activation in Acute-phase Response through Its YXXQ Motif* , 2003, The Journal of Biological Chemistry.

[22]  Y. Sekine,et al.  Signal transducer and activator of transcription 3 regulation by novel binding partners. , 2015, World journal of biological chemistry.

[23]  A. Yoshimura,et al.  Interactions of STAP-2 with Brk and STAT3 Participate in Cell Growth of Human Breast Cancer Cells* , 2010, The Journal of Biological Chemistry.

[24]  A. Yoshimura,et al.  The protein content of an adaptor protein, STAP-2 is controlled by E3 ubiquitin ligase Cbl. , 2009, Biochemical and biophysical research communications.

[25]  E. Nishida,et al.  Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway , 2002, Nature Cell Biology.

[26]  L. Seymour,et al.  Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Brugge,et al.  Controlled Dimerization of ErbB Receptors Provides Evidence for Differential Signaling by Homo- and Heterodimers , 1999, Molecular and Cellular Biology.

[28]  S. Akira,et al.  Modulation of TLR4 Signaling by a Novel Adaptor Protein Signal-Transducing Adaptor Protein-2 in Macrophages1 , 2006, The Journal of Immunology.

[29]  K. Herrup,et al.  Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. , 1995, Science.

[30]  H. Sakurai,et al.  TAK1-Mediated Serine/Threonine Phosphorylation of Epidermal Growth Factor Receptor via p38/Extracellular Signal-Regulated Kinase: NF-κB-Independent Survival Pathways in Tumor Necrosis Factor Alpha Signaling , 2009, Molecular and Cellular Biology.